Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial
<p><strong>Background:</strong> Vancomycin is the most widely used antibiotic for neonatal Gram-positive sepsis, but clinical outcome data of dosing strategies are scarce. The NeoVanc programme comprised extensive preclinical studies to inform a randomised controlled trial to asses...
Main Authors: | , , , , , , , , , , , , , , , , , , , |
---|---|
格式: | Journal article |
語言: | English |
出版: |
Elsevier
2021
|